Haisco Pharmaceutical Group (002653.SZ): The clinical trial application for the innovative drug HSK51155 tablets has been approved.
Hesai Science (002653.SZ) announced that the company has recently received the "Notice of Approval for Clinical Trials of Drugs" for HSK51155 tablets issued by the National Medical Products Administration. HSK51155 is an orally administered small-molecule analgesic independently developed by the company with independent intellectual property rights, and it is intended for the clinical treatment of migraines. HSK51155 is expected to provide a safer and more effective analgesic option for pain patients by controlling pain while reducing the occurrence of adverse reactions and avoiding the risk of addiction.
Haisco Pharmaceutical Group (002653.SZ) recently announced that the National Medical Products Administration has issued the "Clinical Trial Approval Notice" for HSK51155 tablets. HSK51155 is an orally administered small molecule analgesic drug independently developed by the company, intended for the treatment of migraines in clinical settings. HSK51155 is expected to meet patients' pain control needs while minimizing adverse reactions and avoiding the risk of addiction, providing a safer and more effective analgesic option for pain patients.
Related Articles
Hong Kong Stock Concept Tracking | Demand Peak Combined with Supply Structure Optimization, Valuation Repair in the Coal Sector is Expected (Including Concept Stocks)
EB SECURITIES: Performance in the first half of the year shows steady growth, maintaining a "Buy" rating on 361 DEGREES (01361)
EB SECURITIES: Maintains a "Buy" rating on COWELL (01415), optimistic about its continued growth amid the trend of optical upgrades in smartphones.
Hong Kong Stock Concept Tracking | Demand Peak Combined with Supply Structure Optimization, Valuation Repair in the Coal Sector is Expected (Including Concept Stocks)
EB SECURITIES: Performance in the first half of the year shows steady growth, maintaining a "Buy" rating on 361 DEGREES (01361)
EB SECURITIES: Maintains a "Buy" rating on COWELL (01415), optimistic about its continued growth amid the trend of optical upgrades in smartphones.
RECOMMEND
